Published in final edited form as:

Eur J Med Chem. 2008 June ; 43(6): 1304–1308.

Nitrile analogs of meperidine as high affinity and selective sigma-1 receptor ligands

Susan L. Mercer^a, Jamaluddin Shaikh^b, John R. Traynor^c, Rae R. Matsumoto^b, and Andrew Coop^{a*}

^aDepartment of Pharmaceutical Sciences, University of Maryland, School of Pharmacy, 20 Penn Street, Baltimore, MD 21201, USA

^bDepartment of Pharmacology, University of Mississippi, 303 Faser Hall, University, MS 38677, USA

^cDepartment of Pharmacology, University of Michigan, Ann Arbor, MI 48109, USA

Abstract

A series of *N*-substituted-4-cyano-4-phenylpiperidine analogs were synthesized and evaluated for binding affinity at opioid receptors and showed no affinity. The series similarity to previously reported σ ligands prompted analysis at σ receptors to determine the SAR for affinity at σ receptors. Within the *N*-substituent series the saturated analogs showed increased affinity at both σ receptors. Optimal chain length in the *N*-arylalkyl series for σ_1 and σ_2 receptors proved to be *N*-propylphenyl; extension to a four carbon chain dramatically decreased affinity at both receptors. Substituents in the 4-position affects only σ_1 affinity; no change in affinity at σ_2 was shown. The *N*-isobutyl, *N*-phenylpropyl, and *N*-benzyl analogs are worth pursuing due to their good affinity and selectivity at the σ_1 receptor, whereas the *N*-benzyl analog exhibits the greatest selectivity for σ_1 .

Keywords

σ receptor; AC927; UMB24; *N*-substituted piperidines

1. Introduction

σ Receptors were initially classified as subtypes of the opioid class of receptors by Martin et al.[1], but his classification is no longer applied since most of the σ receptor-mediated effects are not sensitive to the opioid antagonist, naloxone [2]. σ Receptors are widely distributed throughout the body [3], with locations in many peripheral organs [4–6], but they are concentrated in the central nervous system, particularly in brainstem motor regions [7,8]. Further research clarified that σ receptors were a unique class of receptors consisting of two established subtypes, σ_1 and σ_2 [9]. Pharmacological effects at the σ_1 receptor include neuroprotection and motor effects, whereas effects at the σ_2 receptor include apoptosis and cell death [10]. That many of the early σ ligands interacted with numerous other biological systems complicated much of the σ receptor literature, and thus there remains an urgent need for the development of high affinity and selective ligands for both receptor subtypes to aid in the further elucidation of σ receptor mechanism(s).

*Corresponding author (AC). Tel.: +1-410-706-2029; fax: +1-410-706-5017; E-mail address: acoop@rx.umaryland.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

We recently published a series of *N*-substituted meperidine analogs [11] during which synthesis, novel and previously reported *N*-substituted nitrile piperidine intermediates were isolated. A representative sample of the nitrile intermediates were analyzed for binding affinity at the opioid receptors, and showed no significant affinity at the mu (μ), kappa (κ), or delta (δ) opioid receptors ($K_i > 10,000$ nM). Their similarity to previously reported σ ligands including **AC927** and **UMB24** (Figure 1) prompted analysis for their binding affinity at the σ receptors. **AC927** (*N*-phenethylpiperidine), a selective σ receptor antagonist, has affinity at both σ_1 and σ_2 receptors [12] and has been used in the development of both σ_1 [13] and σ_2 [14] pharmacophores and regulates cell proliferation pathways [15]. Preliminary studies also show that **AC927** attenuates the locomotor stimulant and neurotoxic effects of methamphetamine in mice [16,17]. **UMB24** (1-(2-phenylethyl)-4-(2-pyridyl)piperazine) has recently been shown to be a σ_2 preferring compound [12,18] which significantly attenuates cocaine-induced convulsions and locomotor activity [18].

Herein we focus on the comparison of the *N*-substituted nitrile piperidine analogs (**2–10**) as well as comparison to **AC927** and **UMB24** to determine the Structure Activity Relationship (SAR) of ligand affinity at the σ_1 and σ_2 receptors. Comparative investigation will determine the relevance of: 1) unsaturation and branching two carbons away from the piperidine nitrogen; 2) the distance of a phenyl ring from the piperidine nitrogen; and 3) influence of substituents in the 4-position.

2. Chemistry

A range of novel and previously reported *N*-substituted nitrile analogs of meperidine were prepared from nitrile (**1**) (obtained from Sigma-Aldrich, Inc.), via alkylation with alkyl halides in DMF in the presence of K_2CO_3 (Scheme 1) to produce **2–10** (Figure 1).

3. Pharmacology

The compounds synthesized in this manuscript are similar to meperidine, a known μ opioid analgesic and other known σ ligands. Therefore, the compounds were evaluated at the three opioid receptors (μ , κ , δ) as previously described [19] (Table 1) and also at the two established σ receptor subtypes (σ_1 , σ_2) as previously described [18,20] (Table 1).

4. Results and discussion

A representative sample of test compounds (**2, 3, 5, 7, 10**) was evaluated for opioid binding and was found to have no significant affinity for the opioid receptors (Table 1). Three test compounds exhibited subnanomolar affinity for the σ_1 receptor; compounds **6, 9** and **7** showed K_i values of 0.35, 0.38, and 0.41 nM, respectively. Compounds **9** and **6** showed the greatest affinity at the σ_2 receptor with affinities of 46 and 63 nM, respectively. Compound **7** (*N*-benzyl) exhibited the highest selectivity for the σ_1 receptor over the σ_2 receptor by a factor of 1600, whereas the *N*-Me (**2**) showed weak affinity at both σ receptors.

The series of *N*-alkyl substituted analogs (**2–6**) all showed high affinity for σ_1 receptors, with little if any difference in affinity with the exception of **2**. This indicates that a larger *N*-alkyl group leads to good σ_1 affinity, but the exact nature of the group (branching, unsaturation) is unimportant. The highest affinity for the σ_2 receptor was 63 nM by compound **6**, followed by **4, 5, 3**, and **2** with affinities of 143, 482, 662, and 2140 nM, respectively. Higher affinities at σ_2 were exhibited for saturated compounds **4** and **6** compared to the corresponding unsaturated compounds **3** and **5**. Overall, compound **6** has the highest affinity for both the σ_1 and σ_2 receptors with a selectivity of 180, while **3** has the highest selectivity in this series with a selectivity of 300.

Compounds **9** (*N*-phenylpropyl) and **7** (*N*-benzyl) have similar high affinity for the σ_1 receptor, with **8** (*N*-phenethyl) 10-fold lower, and **10** (*N*-phenylbutyl) 10-fold lower still. Thus, a nitrogen to phenyl ring chain length of 1–3 carbons is well tolerated at the σ_1 receptor with relatively high affinity, but extension of chain length to 4 carbons decreases affinity. Compound **9** also exhibits the highest affinity at the σ_2 receptor (46 nM), with the others in this series somewhat lower. Overall, compound **9** (*N*-phenylpropyl) exhibits the best affinity for both the σ_1 and σ_2 receptors with a selectivity of 120, while **7** (*N*-benzyl) has the highest selectivity in this series with a selectivity of 1600.

AC927, **UMB 24** and **8** all contain an *N*-phenethyl substituent, but significantly vary in their 4-position substituent, allowing preliminary analysis of the 4-aryl substituent. **8** exhibits the highest affinity for σ_1 receptors (3.3 nM) followed by **AC927** and **UMB24** with affinities of 30 and 322 nM, respectively. The 4-cyano-4-phenyl substituent of **8** is superior to no 4-substituent (**AC927**) and a piperazine (**UMB24**). The 4-position substituent does not appear to significantly influence affinity at the σ_2 receptor. Compound **8** has greater selectivity than **AC927** for σ_1 over σ_2 receptors by a factor of 36 compared to 5; **UMB24** is σ_2 selective. Overall, substituents in the piperidine 4-position affect σ_1 binding affinity but do not affect σ_2 binding affinity.

5. Conclusion

Analysis of the *N*-substituted nitrile piperidine analogs at σ receptors led to selective σ_1 ligands. Compounds **6**, **7**, and **9** are worth pursuing as high affinity selective ligands due to their subnanomolar affinity at the σ_1 receptor. The high affinity of the *N*-benzyl substituent is consistent with previously reported compounds [21]. Compounds **6** and **9** also have good affinity at the σ_2 receptor, whereas compound **7** with 1600 fold selectivity for σ_1 over σ_2 and no affinity at opioid receptors appears to be an ideal ligand for study of σ_1 receptor function. These σ_1 selective ligands with no opioid affinity will further aid in the investigation between the σ_1 and opioid receptors [29].

6. Experimental Protocols

6.1 Chemistry

All reactions were performed under an atmosphere of nitrogen, and all solvents were removed on a rotary evaporator under reduced pressure. TLC was performed on plates coated with silica gel GHLF-0.25 mm plates (60 F₂₅₄) (Analtech). Mass spectra were obtained on a ThermoFinnigan LCQ Classic. ¹H NMR spectra were obtained in CDCl₃ on a Varian Inova 500 MHz instrument in δ units using TMS as an internal standard. Melting points were determined on a Mel-Temp (Laboratory Devices) apparatus and are uncorrected. Elemental analyses were conducted by Atlantic Microlabs (Norcross, Georgia USA) and were within $\pm$ 0.4% of the theoretical values.

General Procedure for the Synthesis of *N*-substituted Nitrile Meperidine

Analog (2, 3, 5, 7–10)—The appropriate halogenated compound (1 eq.) and K₂CO₃ (10 eq.) were added to a solution of freebased 4-cyano-4-phenylpiperidine (Sigma Aldrich) (1 eq.) in DMF (20 mL/g). After stirring overnight at room temperature, H₂O (3x amount of DMF) was added. The reaction mixture was extracted into Et₂O, washed with brine, and dried (Na₂SO₄). Removal of the solvent under reduced pressure gave the crude compound. All compounds were converted to salts by either recrystallization or lyophilization.

6.1.1. 1-methyl-4-phenylpiperidine-4-carbonitrile hydrochloride (2)—RX=methyl iodide (Sigma-Aldrich); Purified by flash chromatography (SiO₂/1:20 MeOH-CHCl₃); Lyophilized with 1M HCl to produce salt; yield 54%; mp 206–211°C; ¹H NMR (CDCl₃) δ

7.54 (d, 7.80 Hz, 2H), 7.43 (t, 7.37 Hz, 2H), 7.36 (t, 6.50, 1H), 2.99 (d, 12.14 Hz, 2H), 2.52 (t, 11.70 Hz, 2H), 2.42 (s, 3H), 2.15 (t, 11.70 Hz, 4H); MS (ESI) m/z = 201.28 ($M + H^+$); Anal. ($C_{13}H_{17}ClN_2 \cdot 0.25H_2O$) C, H, N.

6.1.2. 1-allyl-4-phenylpiperidine-4-carbonitrile hydrochloride (3)—RX=allyl bromide (Sigma-Aldrich); Purified by flash chromatography ($SiO_2/1:20$ MeOH- $CHCl_3$); Lyophilized with 1M HCl to produce salt; yield 59%; mp 237–240°C; 1H NMR ($CDCl_3$) δ 7.51 (d, 7.35 Hz, 2H), 7.40 (t, 7.12 Hz, 2H), 7.33 (t, 7.35 Hz, 1H), 5.88 (m, 1H), 5.25 (s, 2H), 5.20 (t, 9.64 Hz, 2H), 3.11 (d, 5.51 Hz, 2H), 3.05 (d, 11.31 Hz, 2H), 2.49 (t, 11.00 Hz, 2H), 2.12 (s, 2H); MS (ESI) m/z = 227.15 ($M + H^+$); Anal. ($C_{15}H_{19}ClN_2$) C, H, N.

6.1.3. 1-(2-methylallyl)-4-phenylpiperidine-4-carbonitrile hydrochloride (5)—RX=3-bromo-2-methyl-propene (Sigma-Aldrich); Purified by flash chromatography ($SiO_2/1:20$ MeOH- $CHCl_3$); Lyophilized with 1M HCl to produce salt; yield 33%; mp 243–245°C; 1H NMR ($CDCl_3$) δ 7.51 (d, 7.58 Hz, 2H), 7.40 (t, 7.58 Hz, 2H), 7.33 (t, 7.18 Hz, 1H), 4.91 (s, 1H), 4.88 (s, 1H), 2.97 (m, 4H), 2.42 (m, 2H), 2.10 (m, 4H), 1.76 (s, 3H); MS (ESI) m/z = 241.17 ($M + H^+$); Anal. ($C_{16}H_{21}ClN_2 \cdot 0.1H_2O$) C, H, N.

6.1.4. 1-benzyl-4-phenylpiperidine-4-carbonitrile oxalate (7)—RX=benzyl bromide (Sigma-Aldrich). Purified from MeOH and oxalic acid to produce oxalate salt; yield 65%; mp 244–245°C; NMR consistent with previously reported spectra[22]; MS (ESI) m/z = 277.17 ($M + H^+$); Anal. ($C_{21}H_{22}N_2O_4$) C, H, N.

6.1.5. 1-phenylethyl-4-phenylpiperidine-4-carbonitrile trifluoroacetate (8)—RX=2-bromoethyl benzene (Sigma-Aldrich); Purified by flash chromatography ($SiO_2/1:20$ MeOH- $CHCl_3$); Lyophilized with 1M TFA to produce salt; yield 30%; mp 182–187°C; 1H NMR ($CDCl_3$) δ 7.60 (d, 7.27 Hz, 4H), 7.48 (m, 4H), 7.38 (m, 2H), 3.19 (d, 11.55 Hz, 2H), 3.05 (t, 7.49 Hz, 2H), 2.93 (t, 7.70 Hz, 2H), 2.81 (t, 7.49 Hz, 2H), 2.67 (t, 11.33 Hz, 2H), 2.22 (m, 2H); MS (ESI) m/z = 291.18 ($M + H^+$); Anal. ($C_{22}H_{23}F_3N_2O_2$) C, H, N.

6.1.6. 1-phenylpropyl-4-phenylpiperidine-4-carbonitrile trifluoroacetate (9)—RX=1-bromo-3-phenylpropane (Sigma-Aldrich). Purified by flash chromatography ($SiO_2/1:20$ MeOH- $CHCl_3$). Lyophilized with 1M TFA to produce salt; yield 35%; mp 140–145°C; 1H NMR ($CDCl_3$) δ 7.50–7.19 (m, 10H), 3.03 (d, 11.93 Hz, 2H), 2.71 (t, 7.33 Hz, 2H), 2.66 (t, 7.46 Hz, 2H), 2.48 (t, 6.71 Hz, 2H), 2.11 (s, 2H), 2.00 (t, 7.33 Hz, 2H), 1.86 (t, 7.21 Hz, 2H); MS (ESI) m/z = 305.20 ($M + H^+$); Anal. ($C_{21}H_{24}N_2 \cdot 0.8C_2HF_3O_2$) C, H, N.

6.1.7. 1-phenylbutyl-4-phenylpiperidine-4-carbonitrile oxalate (10)—RX=1-chloro-4-phenylbutane (Sigma-Aldrich); Purified from acetone and oxalic acid to produce oxalate salt; yield 34%; mp 210–211°C; 1H NMR ($CDCl_3$) δ 7.51 (d, 7.11 Hz, 4H), 7.41 (t, 7.44 Hz, 4H), 7.33 (t, 7.28 Hz, 2H), 3.18 (m, 4H), 2.10 (d, 12.61 Hz, 2H), 2.00 (m, 2H), 1.56 (m, 8H); MS (ESI) m/z = 319.21 ($M + H^+$).

General Hydrogenation Procedure (4, 6) derived from Maeda et al [23]—A suspension of 10% Pd/C in EtOH (1 mL) was added to a solution of alkene (1 eq.) and NH_4HCO_2 (10 eq.) in EtOH (20 mL/g). After refluxing overnight and cooling, the solution was filtered through Celite and the solvent removed under reduced pressure. The resulting residue was redissolved in EtOAc, washed with brine, and dried (Na_2SO_4). Removal of the solvent under reduced pressure yielded the crude compound. Compounds were purified using flash chromatography ($SiO_2/1:20$ MeOH- $CHCl_3$) and converted to salts.

6.1.8. 1-propyl-4-phenylpiperidine-4-carbonitrile oxalate (4)—Recrystallized from acetone and oxalic acid to produce oxalate salt; yield 27%; mp 170°C; ^1H NMR (CDCl_3) δ 7.59 (d, 7.75 Hz, 2H), 7.45 (m, 3H), 4.12 (q, 6.97 Hz, 2H), 3.80 (d, 13.75, 1H), 3.65 (m, 1H), 3.49 (s, 1H), 3.13 (d, 9.71 Hz, 1H), 2.98 (t, 7.77 Hz, 1H), 2.22 (d, 10.68 Hz, 1H), 2.05 (s, 2H), 1.26 (t, 7.21 Hz, 3H), 1.06 (t, 7.31, 1H), 0.91 (m, 1H); MS (ESI) $m/z = 229.40$ ($M + H^+$); Anal. ($\text{C}_{17}\text{H}_{22}\text{N}_2\text{O}_4 \cdot \text{H}_2\text{O}$) C, H, N.

6.1.9. 1-isobutyl-4-phenylpiperidine-4-carbonitrile trifluoroacetate (6)—Lyophilized with 1M TFA to produce salt; yield 21%; mp 144–147°C; ^1H NMR (CDCl_3) δ 7.45 (m, 4H), 7.37 (t, 6.94 Hz, 1H), 4.64 (m, 1H), 4.22 (m, 1H), 3.80 (m, 1H), 3.62 (m, 1H), 3.12 (m, 1H), 2.20 (m, 4H), 1.97 (m, 2H), 1.62 (m, 3H), 0.92 (m, 2H); MS (ESI) $m/z = 243.18$ ($M + H^+$); Anal. ($\text{C}_{18}\text{H}_{23}\text{F}_3\text{N}_2\text{O}_2$) C, H, N.

6.2 Sigma Pharmacology

Competition binding assays were performed in homogenates from rat brain minus cerebellum (450–500 μg protein/tube) using procedures previously described in detail [18,20,24]. The assays were conducted in 50 mM Tris-HCl, pH 8.0 using a total volume of 500 μL /tube. σ_1 Receptors were labeled using 5 nM [^3H](+)-pentazocine; σ_2 receptors were labeled with 3 nM [^3H]di-o-tolylguanidine in the presence of 300 nM (+)-pentazocine to mask σ_1 receptors. Non-specific binding was determined in the presence of 10 μM haloperidol. Twelve concentrations of test ligand were used in each assay. After incubation for 120 min at 25°C, the assays were terminated with the addition of ice-cold 10 mM Tris-HCl, pH 8.0 and vacuum filtration through glass fiber filters. K_i values were calculated from the data using Graph Pad Prism and previously determined K_d values.

7. Acknowledgments

The authors thank Drs. Kellie Hom and Julie Ray for their excellent technical assistance. These studies were supported in part by the National Institute on Drug Abuse, National Institutes of Health (NIDA, NIH) (DA013583, DA013978, and DA000254) and also the University of Maryland, School of Pharmacy. SLM is supported by a Fellowship from the University of Maryland, School of Pharmacy. AC is supported by an Independent Scientist Award (K02 DA019634).

8. References

- Martin WR, Eades CG, Thompson JA, Huppler RE, Gilbert PE. J. Pharmacol. Exp. Ther 1976;197:517–532. [PubMed: 945347]
- Tam SW. Proc. Natl. Acad. Sci 1983;80:6703–6707. [PubMed: 6314335]
- Matsumoto RR, Liu Y, Lerner M, Howard EW, Brackett DJ. Eur. J. Pharmacol 2003;469:1–12. [PubMed: 12782179]
- Kawamura K, Ishiwata K, Tajima H, Ishii S, Shimada Y, Matsuno K, Homma Y, Senda M. Nucl. Med. Biol 1999;26:915–922. [PubMed: 10708305]
- Kawamura K, Ishiwata K, Tajima H, Ishii S, Matsuno K, Homma Y, Senda M. Nucl. Med. Biol 2000;27:255–261. [PubMed: 10832082]
- Wolfe SA Jr, Culp SG, De Souza EB. Endocrinology 1989;124:1160–1172. [PubMed: 2537173]
- Bouchard P, Quirion R. Neuroscience 1997;76:467–477. [PubMed: 9015331]
- Walker JM, Bowen WD, Walker FO, Matsumoto RR, De Costa B, Rice KC. Pharmacol. Rev 1990;42:355–402. [PubMed: 1964225]
- Hellewell SB, Bruce A, Feinstein G, Orringer J, Williams W, Bowen WD. Eur. J. Pharmacol 1994;268:9–18. [PubMed: 7925616]
- Newman, AH.; Coop, A. Sigma Receptors: Chemistry, Cell Biology and Clinical Implications. Matsumoto, RR.; Bowen, WD.; Su, TP., editors. New York: Springer; 2007. p. 25-44.
- Mercer SL, Hassan HE, Cunningham CW, Eddington ND, Coop A. Bioorg. Med. Chem. Lett 2007;17:1160–1162. [PubMed: 17251015]

12. Maeda DY, Williams W, Kim WE, Thatcher LN, Bowen WD, Coop A. *Bioorg. Med. Chem. Lett* 2002;12:497–500. [PubMed: 11814827]
13. Jung D, Floyd J, Gund TM. *J. Comput. Chem* 2004;25:1385–1399. [PubMed: 15185333]
14. Cratteri P, Romanelli MN, Cruciani G, Bonaccini C, Melani F. *J. Comput. Aided Mol. Des* 2004;18:361–374. [PubMed: 15595462]
15. Crawford KW, Coop A, Bowen WD. *Eur. J. Pharmacol* 2002;443:207–209. [PubMed: 12044812]
16. Matsumoto RR, Shaikh J, Wilson LL, Wang JJ, Coop A. *FASEB J* 2007;21:A777.
17. Shaikh J, Matsumoto RR. *FASEB J* 2007;19:A1081.
18. Matsumoto RR, Pouw B, Mack AL, Daniels A, Coop A. *Pharmacol. Biochem. Behav* 2007;86:86–91. [PubMed: 17241657]
19. Traynor, JR.; Woods, JH. Drug Evaluation Committee Report on Evaluation of New Compounds for Opioid Activity. Dewey, WL., editor. Vol 186. Bethesda, MD: National Institute on Drug Abuse Research Monograph Series, U.S. Department of Health and Human Services, National Institutes of Health; 2005. p. 163–186.
20. Daniels A, Ayala E, Chen W, Coop A, Matsumoto RR. *Eur. J. Pharmacol* 2006;542:61–68. [PubMed: 16797004]
21. Ablordeppey, SY.; Glennon, RA. Sigma Receptors: Chemistry, Cell Biology and Clinical Implications. Matsumoto, RR.; Bowen, WD.; Su, TP., editors. New York: Springer; 2007. p. 71–98.
22. McMahon RE, Culp HW, Cymerman CJ, Ekwuribe N. *J. Med. Chem* 1979;22:1100–1103. [PubMed: 490556]
23. Maeda DY, Coop A. *Tetrahedron* 2000;56:7399–7402.
24. Matsumoto RR, McCracken KA, Pouw B, Zhang Y, Bowen WD. *Neuropharmacology* 2002;42:1043–1055. [PubMed: 12128006]
25. Eisleb O. *Chem Ber* 1941;74:1433–1450.
26. Morrison A, Rinderknecht H. *J. Chem. Soc* 1950:1467–1469.
27. Thompson D, Reeves PC. *J. Heterocycl. Chem* 1983;20:771–772.
28. Rehse K, Werner U. *Archiv. der Pharmazie* 1986;319:505–515. [PubMed: 3090975]
29. Mei J, Pasternak GW. *J. Pharmacol. Exp. Ther* 2007;322:1278–1285. [PubMed: 17545312]

Figure 1.

Scheme 1.

Reagents and conditions: (a) RX, K₂CO₃, DMF

Table 1
Binding affinities of test compounds (2–10), AC927, and UMB24.

R	Nitrile	Opioid Binding		Sigma Binding			
		Ki (nM) ± SEM		Ki (nM) ± SEM			
		μ	κ	δ	σ ₁ ^a	σ ₂ ^b	Selectivity σ ₂ /σ ₁
CH ₃	2 [25]	> 10000	> 10000	> 10000	113 ± 5.5	2142 ± 364	19
CH ₂ CH=CH ₂	3 [26]	> 10000	> 10000	> 10000	2.2 ± 0.33	662 ± 78	300
(CH ₂) ₂ CH ₃	4	NT	NT	NT	1.7 ± 0.22	143 ± 13	84
CH ₂ C(CH ₃)=CH ₂	5	> 10000	> 10000	5000 ± 1300	3.7 ± 0.83	482 ± 48	130
CH ₂ CH(CH ₃) ₂	6 [27]	NT	NT	NT	0.35 ± 0.01	63 ± 2.7	180
CH ₂ (C ₆ H ₅)	7 [25]	5900 ± 90	> 10000	> 10000	0.41 ± 0.08	657 ± 19	1600
(CH ₂) ₂ (C ₆ H ₅)	8	NT	NT	NT	3.3 ± 0.38	118 ± 2.6	36
(CH ₂) ₃ (C ₆ H ₅)	9	NT	NT	NT	0.38 ± 0.04	46 ± 5.5	120
(CH ₂) ₄ (C ₆ H ₅)	10 [28]	9800 ± 680	> 10000	> 10000	49 ± 3.2	1310 ± 215	27
AC927					30 ± 2	138 ± 18	5
UMB24					322 ± 32	170 ± 5	0.53

Citations reference previously known compounds and/or results.

^a Displacement of [³H](+)-pentazocine.

^b Displacement of [³H]DTG in the presence of (+)-pentazocine.

NT = not tested

Analytical Data (for Manuscript Reviewers)

Compound Number	Calculated (%)			Found (%)		
	C	H	N	C	H	N
2 • 0.25 H ₂ O	64.72	7.31	11.61	64.94	7.08	11.36
3	68.56	7.29	10.66	68.21	7.15	10.55
4 • 1 H ₂ O	60.70	7.19	8.33	60.55	6.89	8.11
5 • 0.1 H ₂ O	68.98	7.67	10.05	68.87	7.35	9.73
6	60.66	6.50	7.86	60.68	6.47	7.95
7	68.84	6.05	7.65	68.94	6.11	7.61
8	65.34	5.73	6.93	65.84	5.97	7.12
9 (1 fb • 0.8 TFA)	68.61	6.32	7.08	68.47	6.27	6.98
10	CHN not possible, see attached document (Cmpd 10 NMR)					